Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 13

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 13
---
2025 Update
• June: Announcement of the Phase 2 ABBIL1TY MELANOMA-07 (NCT06984328) study of the effectiveness and safety of acasunlimab alone and with pembrolizumab to treat advanced melanoma of the skin that has returned after treatment with an approved checkpoint inhibitor therapy.

GEN1042 (BNT312) – Potential first-in-class bispecific agonistic antibody

• Bispecific antibody targeting CD40 and 4-1BB, created using Genmab’s DuoBody technology platform

• Multiple clinical trials in solid tumors ongoing

• Co-developed in collaboration with BioNTech

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 9/44                   
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
GEN1042 (DuoBody-CD40x4-1BB, BNT312) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1042 on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance activation of both dendritic cells and antigen-dependent T-cells. Three clinical trials of GEN1042 in solid tumors are ongoing.

GEN1059 (BNT314) – Bispecific antibody with potential in solid tumors

• Bispecific antibody targeting EpCAM and 4-1BB, created using Genmab’s DuoBody technology platform

• Phase 1 clinical trial (NCT06150183) in solid tumors is recruiting

• Co-developed in collaboration with BioNTech

GEN1059 (DuoBody-EpCAMx4-1BB, BNT314), jointly owned by Genmab and BioNTech and created using Genmab’s DuoBody technology platform, is a bispecific antibody aimed at boosting antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity. GEN1059 is being co-developed by Genmab and BioNTech under an agreement in which the